High CD20+ background cells predict a favorable outcome in classical Hodgkin lymphoma and antagonize CD68+ macrophages

Leukemia and Lymphoma

Volumn 56, Issue 6, 2015, Pages 1636-1642

  Panico, Luigi ^a   Tenneriello, Valentina ^a   Ronconi, Fioravante ^a,b   Lepore, Marianna ^a   Cantore, Nicola ^a   Dell'Angelo, Antonietta Carmela ^a   Ferbo, Ludovica ^a   Ferrara, Felicetto ^b  

^a S G MOSCATI HOSPITAL   (Italy)

^b CARDARELLI HOSPITAL   (Italy)

Author keywords

CD20; Classical Hodgkin lymphoma; Immunohistochemistry; Microenvironment; Prognosis

Indexed keywords

BLEOMYCIN; CD20 ANTIGEN; CD34 ANTIGEN; CD68 ANTIGEN; DACARBAZINE; DOXORUBICIN; LACTATE DEHYDROGENASE; VINBLASTINE; CD68 ANTIGEN, HUMAN; DIFFERENTIATION ANTIGEN; LEUKOCYTE ANTIGEN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CANCER SURVIVAL; CHILD; CLASSICAL HODGKIN LYMPHOMA; FEMALE; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RETROSPECTIVE STUDY; TUMOR ASSOCIATED LEUKOCYTE; TUMOR MICROENVIRONMENT; HODGKIN DISEASE; MACROPHAGE; METABOLISM; MIDDLE AGED; PATHOLOGY; PROGNOSIS; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD20; ANTIGENS, DIFFERENTIATION, MYELOMONOCYTIC; CHILD; FEMALE; HODGKIN DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MACROPHAGES; MALE; MIDDLE AGED; PROGNOSIS; RETROSPECTIVE STUDIES; YOUNG ADULT;

EID: 84932167406     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2014.951849     Document Type: Article

References (24)

1. Mani H,Jaffe E S. H odgkin lymphoma: An update on its biology with newer insights into classification. Clin Lymphoma Myeloma 2009; 9: 206-216.
2. Pileri SA, Ascani S, Leoncini L, et al. Hodgkin ' s lymphoma: The pathologist ' s viewpoint. J Clin Pathol 2002; 55: 162-176.
3. Piccaluga P P, A gostinelli C, Gazzola A, et al. P athobiology of Hodgkin lymphoma. Adv Hematol 2011; 2011: 920898.
4. Steidl C, Connors JM, Gascoyne RD. Molecular pathogenesis of Hodgkin ' s lymphoma: increasing evidence of the importance of the microenvironment. J Clin Oncol 2011; 29: 1812-1826.
5. Canellos G P, A nderson J R, Propert K J, et al. C hemotherapy of advanced Hodgkin ' s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-1484.
6. Canellos G P, Niedzwiecki D. L ong term follow-up of Hodgkin' s disease trial. N Engl J Med 2002; 346: 1417-1418.
7. Castellino SM, Geiger AM, Mertens AC, et al. Morbidity and mortality in long-term survivors of Hodgkin lymphoma: A report from the childhood cancer survivor study. Blood 2011; 117: 1806-1816.
8. Hasenclever D, Dihel V. A prognostic score for advanced Hodgkin ' s disease. N Engl J Med 1998; 339: 1506-1514.
9. Tubiana M, Henry-Amar H, Carde P, et al. Toward comprehensive management tailored to prognostic factors of patients with clinical stages I and II in Hodgkin ' s disease. The EORTC lymphoma group controlled clinical trials: 1964-1987. Blood 1989; 73: 47-56.
10. Devilard E, Bertucci F, Trempat P, et al. Gene expression profiling defines molecular subtypes of classic Hodgkin ' s disease. Oncogene 2002: 21: 3095-3102.
11. Sanchez-Aguilera A, Montalban C, de la Cueva P, et al. Tumor microenvironment and mitotic checkpoint are key factors in the outcome of classic Hodgkin lymphoma. Blood 2006; 108: 662-668.
12. Chetaille B, Bertucci F, Finetti P, et al. Molecular profiling of classic Hodgkin lymphoma tissue uncovers variations in the tumor microenvironment and correlations with EBV infection and outcome. Blood 2009; 113: 2765-2775.
13. Steidl C, Lee T, Shah S P, et al. T umor- Associ. macrophages and survival in classic Hodgkin ' s lymphoma. N Engl J Med 2010: 362: 875-885.
14. Greaves P, Clear A, Coutinho R, et al. E xpression of FOXP3, CD68 and CD20 at diagnosis in the microenvironment of classical Hodgkin lymphoma is predictive of outcome. J Clin Oncol 2012; 31: 256-262.
15. Tudor CS, Distel LV, Eckhardt J, et al. B cells in Hodgkin lymphoma are important actors rather than bystanders in the local immune reaction. Hum Pathol 2013; 44: 2475-2486.
16. Panico L, Ronconi F, Lepore M, et al. Prognostic role of tumor associated macrophages and angiogenesis in classical Hodgkin lymphoma. Leuk Lymphoma 2013; 54: 2418-2425.
17. Alvaro T, Lejeune M, Salvado MT, et al. Outcome in Hodgkin ' s lymphoma can be predicted from the presence of accompanying cytotoxic and regulatory T cells. Clin Cancer Res 2005; 11: 1467-1473.
18. Kelley TW, Pohlman B, Elson P, et al. The ratio of FOXP3 regulatory T cells to Granzyme B cytotoxic T/NK cells predicts prognosis in classical Hodgkin lymphoma and is independent of bcl-2 and MAL expression. Am J Clin Pathol 2007: 128: 958-965.
19. Molin D, Edstrom A, Glimelius I, et al. M ast cell infiltration correlates with poor prognosis in Hodgkin ' s lymphoma. Br J Hematol 2002; 119: 122-124.
20. Nelson BH. CD20 B cells: The other tumor-infiltrating lymphocytes. J Immunol 2010: 185: 4977-4982.
21. Younes A, Romaguera J, Hagemeister F, et al. A pilot study of rituximab in patients with recurrent, classic Hodgkin lymphoma. Cancer 2003; 98: 310-314.
22. Oki Y, Pro B, Fayad LE, et al. Phase 2 study of gemcitabine in combination with rituximab in patients with recurrent or refractory Hodgkin lymphoma. Cancer 2008; 112: 831-836.
23. Jones RJ, Gocke CD, Kasamon YL, et al. Circulating clonotypic B cells in classic Hodgkin lymphoma. Blood 2009; 113: 5920-5926.
24. Kasamon YL, Jacene HA, Gocke CD, et al. Phase 2 study of rituximab-ABVD in classical Hodgkin lymphoma. Blood 2012; 119: 4129-4132.